ASCOT (women subgroup) 2003

1 Treatments

Studied treatment  Atorvastatin 10 mg daily

Control treatment  placebo

Concomitant treatments  -

initial women proportion in the trial  1942/10305 (19%)

2 Patients

Patients  hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) - subgroup of women

Inclusion criteria  -

Exclusion criteria  -

prior CHD (%)  0%

baseline CT  204 mg/dL

baseline LDL  127 mg/dL

3 Methods

Blinding  double-blind

Design  Parallel groups

Centers  718

Geographical area  Europe

Sizes  979/963

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cv events</td>
<td>19/979</td>
<td>17/963</td>
<td>1,10</td>
<td>[0,57; 2,13]</td>
</tr>
<tr>
<td>All cause mortality</td>
<td>-/979</td>
<td>-/963</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CHD events</td>
<td>19/979</td>
<td>17/963</td>
<td>1,10</td>
<td>[0,57; 2,13]</td>
</tr>
<tr>
<td>cancer</td>
<td>-/979</td>
<td>-/963</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References